ResearcherShandong UniversityNo recent work listed
Guangyong Zhang
Matched on ORCID iD 0000-0001-5308-0129; OpenAlex author ID A5027515470. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper
Papers 5
- FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. Co-author DOI 10.1016/j.canlet.2023.216403↗
- Immunotherapy for pancreatic cancer: A long and hopeful journey. Co-author DOI 10.1016/j.canlet.2018.03.040↗
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Last author DOI 10.1002/cam4.1071↗
- Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Co-author DOI 10.1016/j.canlet.2017.01.041↗
- Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. Co-author DOI 10.1186/s12957-015-0510-0↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jianwei Xu · 4 shared papers, 2015–2018 · strength 0.31
- Paper Immunotherapy for pancreatic cancer: A long and hopeful journey. DOI 10.1016/j.canlet.2018.03.040↗
- Paper Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. DOI 10.1002/cam4.1071↗
- Paper Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. DOI 10.1016/j.canlet.2017.01.041↗
- Sanyuan Hu · 4 shared papers, 2015–2018 · strength 0.31
- Paper Immunotherapy for pancreatic cancer: A long and hopeful journey. DOI 10.1016/j.canlet.2018.03.040↗
- Paper Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. DOI 10.1002/cam4.1071↗
- Paper Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. DOI 10.1016/j.canlet.2017.01.041↗
- Hanxiang Zhan · 2 shared papers, 2017–2023 · strength 0.27
- Lei Wang · 3 shared papers, 2017–2018 · strength 0.25
- Paper Immunotherapy for pancreatic cancer: A long and hopeful journey. DOI 10.1016/j.canlet.2018.03.040↗
- Paper Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. DOI 10.1002/cam4.1071↗
- Paper Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. DOI 10.1016/j.canlet.2017.01.041↗
- Hanxiang Zhan · 3 shared papers, 2015–2018 · strength 0.23
- Paper Immunotherapy for pancreatic cancer: A long and hopeful journey. DOI 10.1016/j.canlet.2018.03.040↗
- Paper Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. DOI 10.1002/cam4.1071↗
- Paper Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. DOI 10.1186/s12957-015-0510-0↗
- Jian Yang · 1 shared paper, 2023 · strength 0.19
- Yongzheng Li · 1 shared paper, 2023 · strength 0.19
- Zhiyao Fan · 1 shared paper, 2023 · strength 0.19
- Bin Zhou · 2 shared papers, 2017–2018 · strength 0.17
- Lei Wang · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.